Liver Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been clinically diagnosed with primary liver cancer (hepatocellular carcinoma, or HCC) — meaning the cancer started in the liver, not spread there from elsewhere
- People aged between 18 and 75 years
- People whose largest liver tumour measures 10 cm or more
- People with intermediate to advanced-stage large liver cancer, or advanced liver cancer with a specific level of blood vessel involvement in the portal vein (types I–III) (confirm with trial site)
- People with a limited number of cancer spread sites — 5 or fewer in total
- People whose liver function falls within a specific scoring range known as Child-Pugh class A or B (confirm with trial site)
- People who are largely able to carry out daily activities, rated 0 or 1 on a standard health performance scale
- People whose blood test results meet specific thresholds, including healthy enough levels of haemoglobin, bilirubin, albumin, liver enzymes, kidney function, and blood clotting (confirm with trial site for exact values)
- People whose blood clotting time falls within an acceptable range
Who may not be able to join:
- People whose liver cancer has come back after previous treatment (recurrent HCC)
- People with more than 5 sites of cancer spread outside the liver
- People with the most severe type of portal vein tumour involvement (type IV), which affects the main intestinal vein
- People with serious other medical conditions
- People showing signs that the liver is no longer functioning adequately, such as fluid build-up in the abdomen, gastrointestinal bleeding, or confusion caused by liver failure
- People rated 2 or higher on the standard health performance scale, indicating more limited daily functioning
- People with a known or suspected allergy to any of the medications used in this trial
- People with heart rhythm problems that require medication to control
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Feng Duan, MD, Chinese PLA General Hospital
Phone: 86 19868000115
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Objective response rate
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.